Sibutramine-associated adverse effects: a practical guide for its safe use. (Q34585304)

3 August 2017

1 reference

title

Sibutramine-associated adverse effects: a practical guide for its safe use. (English)

1 reference

3 August 2017

Evangelos N Liberopoulos

0 references

author name string

Florentin M

series ordinal

1

1 reference

PubMed ID

18034790

3 August 2017

Liberopoulos EN

series ordinal

2

1 reference

PubMed ID

18034790

3 August 2017

Elisaf MS

series ordinal

3

1 reference

3 August 2017

23 November 2007

1 reference

3 August 2017

1 reference

3 August 2017

9

1 reference

3 August 2017

4

1 reference

3 August 2017

378-387

1 reference

Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology

3 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

The epidemiology of central fat distribution in relation to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Clinical pharmacotherapy for obesity: current drugs and those in advanced development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Diagnosis and management of the metabolic syndrome in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

The efficacy and safety of sibutramine for weight loss: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine. A review of its contribution to the management of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Meta-analysis: pharmacologic treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Phentermine, sibutramine and metformin could be used for the prevention and treatment of steroid-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine does not worsen sleep apnea syndrome: a randomized double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

A review of the metabolic effects of sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Weight management and current options in pharmacotherapy: orlistat and sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Prognostic significance of variability in ambulatory and home blood pressure from the Ohasama study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

The role of heart rate in the development of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Paradoxical effect of sibutramine on autonomic cardiovascular regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients--sibutramine and blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

A risk-benefit assessment of anti-obesity drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Effects of the sibutramine therapy on pulmonary artery pressure in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

The New Zealand intensive medicines monitoring programme in pro-active safety surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

QT interval prolongation associated with sibutramine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Pharmacogenetics of cardiac K(+) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine: possible cause of a reversible cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine and panic attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine may be associated with memory impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Role of serotonin in memory impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine use associated with reversible hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

The preconceptual contraception paradigm: obesity and infertility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1467-789X.2007.00425.X

Prevalence and trends in overweight among US children and adolescents, 1999-2000

21 January 2018

1 reference

28 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1001/JAMA.288.14.1728

Identifiers

DOI

10.1111/J.1467-789X.2007.00425.X

1 reference

3 August 2017

1 reference

PubMed ID

18034790